Search This Blog

Monday, June 27, 2022

Capricor: Statistically Significant Clinical Benefits in Duchenne

-Met Primary Endpoint of Performance of the Upper Limb PUL 2.0 (p=0.02)-

-Results Suggest Disease Modification in DMD and Long-term Safety of CAP-1002-

-Results were Presented at Late Breaking Session at PPMD’s Annual Conference on Saturday June 25, 2022-

-Principal Investigator Dr. Craig McDonald and Capricor Management Will Host Conference Call and Webcast Today at 8:00 a.m. ET-

Capricor will host a conference call and webcast with slides today, June 27, 2022, at 8:00 a.m. ET to discuss the data findings. To participate in the conference call, please dial 877-451-6152 (domestic) or 201-389-0879 (international) and reference the access code: 13730622

To participate via a webcast and view the slides, please click here. The webcast will be archived for approximately 30 days and will be available at http://capricor.com/news/events/.

https://finance.yahoo.com/news/capricor-therapeutics-announces-statistically-significant-110000987.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.